A
Anthony D'Amelio
Researcher at Novartis
Publications - 15
Citations - 1500
Anthony D'Amelio is an academic researcher from Novartis. The author has contributed to research in topics: Trametinib & Dabrafenib. The author has an hindex of 8, co-authored 13 publications receiving 1101 citations.
Papers
More filters
Journal ArticleDOI
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard,Egbert F. Smit,Harry J.M. Groen,Julien Mazieres,Benjamin Besse,Åslaug Helland,Vanessa Giannone,Anthony D'Amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce E. Johnson +10 more
TL;DR: Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.
Journal ArticleDOI
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard,Tae Min Kim,Julien Mazieres,Elisabeth Quoix,Gregory J. Riely,Gregory J. Riely,Fabrice Barlesi,Pierre Jean Souquet,Egbert F. Smit,Harry J.M. Groen,Harry J.M. Groen,Ronan J. Kelly,Byoung Chul Cho,Mark A. Socinski,Lini Pandite,Christine Nase,Bo Ma,Anthony D'Amelio,Bijoyesh Mookerjee,C. Martin Curtis,Bruce E. Johnson +20 more
TL;DR: Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC and could represent a treatment option for a population of patients with limited therapeutic options.
Journal ArticleDOI
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.
David Planchard,Benjamin Besse,Tae Min Kim,Elisabeth Quoix,Pierre Jean Souquet,Julien Mazieres,Fabrice Barlesi,Harry J.M. Groen,Egbert F. Smit,Christina S. Baik,Byoung Chul Cho,Ronan J. Kelly,Mark A. Socinski,Silvia Novello,James R. Rigas,Vanessa Giannone,Anthony D'Amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce E. Johnson +19 more
TL;DR: An updated survival analysis is presented based on additional follow-up of initial cohorts of the BRF113928 trial, finding durable response was observed in D + T pts and investigator-assessed ORR was 33.3% and 63.2% in pts who received D or D +T, respectively.
Journal ArticleDOI
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Caroline Robert,Keith T. Flaherty,Paul Nathan,Peter Hersey,Claus Garbe,Mohammed M. Milhem,Lev V. Demidov,Peter Mohr,Jessica C. Hassel,Piotr Rutkowski,Reinhard Dummer,Jochen Utikal,Felix Kiecker,James Larkin,Anthony D'Amelio,Bijoyesh Mookerjee,Dirk Schadendorf +16 more
TL;DR: This 5-year follow-up of patients with BRAF V600 E/K-mutant metastatic melanoma on a targeted therapy demonstrates that long-term use of trametinib is possible with no new or unexpected adverse events.
Journal ArticleDOI
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Axel Hauschild,Paolo A. Ascierto,Dirk Schadendorf,Jean-Jacques Grob,Antoni Ribas,Felix Kiecker,Caroline Dutriaux,Lev V. Demidov,Céleste Lebbé,Piotr Rutkowski,Christian U. Blank,Ralf Gutzmer,Michael Millward,Richard F. Kefford,Tomas Haas,Anthony D'Amelio,Eduard Gasal,Bijoyesh Mookerjee,Paul B. Chapman +18 more
TL;DR: Dabrafenib improved PFS versus dacarbazine, regardless of baseline lactate dehydrogenase levels, and extended follow-up shows that durable benefit lasting ≥5 years is achievable in a subset of patients.